213 related articles for article (PubMed ID: 27799438)
1. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs.
Feldman CH; Liu J; Feldman S; Solomon DH; Kim SC
Lupus; 2017 Jun; 26(7):682-689. PubMed ID: 27799438
[TBL] [Abstract][Full Text] [Related]
2. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.
Kim SC; Glynn RJ; Giovannucci E; Hernández-Díaz S; Liu J; Feldman S; Karlson EW; Schneeweiss S; Solomon DH
Ann Rheum Dis; 2015 Jul; 74(7):1360-7. PubMed ID: 24618265
[TBL] [Abstract][Full Text] [Related]
3. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study.
Kim SC; Schneeweiss S; Liu J; Karlson EW; Katz JN; Feldman S; Solomon DH
Arthritis Rheumatol; 2016 Sep; 68(9):2106-13. PubMed ID: 27015113
[TBL] [Abstract][Full Text] [Related]
4. Cervical neoplasia in systemic lupus erythematosus: a nationwide study.
Wadström H; Arkema EV; Sjöwall C; Askling J; Simard JF
Rheumatology (Oxford); 2017 Apr; 56(4):613-619. PubMed ID: 28039412
[TBL] [Abstract][Full Text] [Related]
5. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.
Feldman CH; Hiraki LT; Winkelmayer WC; Marty FM; Franklin JM; Kim SC; Costenbader KH
Arthritis Rheumatol; 2015 Jun; 67(6):1577-85. PubMed ID: 25772621
[TBL] [Abstract][Full Text] [Related]
6. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?
Klumb EM; Araújo ML; Jesus GR; Santos DB; Oliveira AV; Albuquerque EM; Macedo JM
J Clin Rheumatol; 2010 Jun; 16(4):153-7. PubMed ID: 20407390
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with abnormal Pap results in systemic lupus erythematosus.
Bernatsky S; Ramsey-Goldman R; Gordon C; Joseph L; Boivin JF; Rajan R; Allen A; Moore AD; Leung MH; Clarke A
Rheumatology (Oxford); 2004 Nov; 43(11):1386-9. PubMed ID: 15280571
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort.
Mok CC; Tse SM; Chan KL; Ho LY
Lupus; 2018 Apr; 27(5):722-727. PubMed ID: 29087260
[TBL] [Abstract][Full Text] [Related]
10. Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not Related to Disease Severity.
Dhar JP; Gregoire L; Lancaster W; Stark A; Schwartz AG; Schultz D; Essenmacher L; Ager J; Chiodo L; Husain M; Sokol RJ
Curr Rheumatol Rev; 2013; 9(4):301-4. PubMed ID: 26932295
[TBL] [Abstract][Full Text] [Related]
11. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
Feldman CH; Yazdany J; Guan H; Solomon DH; Costenbader KH
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1712-21. PubMed ID: 26097166
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort.
Yang SC; Lai YY; Huang MC; Tsai CS; Wang JL
Lupus; 2018 Oct; 27(11):1819-1827. PubMed ID: 30103646
[TBL] [Abstract][Full Text] [Related]
13. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
14. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
Feldman CH; Marty FM; Winkelmayer WC; Guan H; Franklin JM; Solomon DH; Costenbader KH; Kim SC
Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study.
Tam LS; Chan PK; Ho SC; Yu MY; Yim SF; Cheung TH; Wong MC; Cheung JL; Li EK
Arthritis Care Res (Hoboken); 2011 Feb; 63(2):269-76. PubMed ID: 20890985
[TBL] [Abstract][Full Text] [Related]
16. Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study.
Lo CH; Wang YH; Tsai CF; Chan KC; Li LC; Lo TH; Wei JC; Su CH
PLoS One; 2021; 16(5):e0251918. PubMed ID: 34015030
[TBL] [Abstract][Full Text] [Related]
17. [Does a particular risk associated with papillomavirus infections exist in women with lupus?].
Berthier S; Mougin C; Vercherin P; Desmurs H; Gil H; de Wazières B; Dupond JL
Rev Med Interne; 1999 Feb; 20(2):128-32. PubMed ID: 10227090
[TBL] [Abstract][Full Text] [Related]
18. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
[TBL] [Abstract][Full Text] [Related]
19. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Haugaard JH; Dreyer L; Ottosen MB; Gislason G; Kofoed K; Egeberg A
J Am Acad Dermatol; 2021 Apr; 84(4):930-937. PubMed ID: 33321159
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
Chang JC; Costenbader KH
Semin Arthritis Rheum; 2022 Oct; 56():152042. PubMed ID: 35738041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
